title: [Assessment of staging and prognostic scoring system for malignant trophoblastic neoplasia].
abstract: OBJECTIVE
  To assess malignant trophoblastic neoplasia with the standards of the clinical stage and prognostic factor scoring system.
  
  
  METHODS
  Through assessing the high-risk factors except clinical stages for 223 patients before treatment according to International Federation of Gynecology and Obstetrics (FIGO) scoring system published in 2000, appropriate treatments were selected for the different patients.
  
  
  RESULTS
  Forty-three of 78 cases of choriocarcinomas were with high-risk factors, the other 35 cases were with low-risk factors; 7 of 145 cases of invasive moles were with high-risk factors and the others were with low-risk factors. The primary chemotherapy principle was that one agent was used for those patients with low-risk factors and two or multiple-agents were used for those patients with high-risk factors. Among all patients, the one-year, three-year and five-year survival rates were 98.6%, 98.1% and 97.1% respectively. No patient died of drug toxicity or complication.
  
  
  CONCLUSIONS
  Selection of treatment approaches according to the prognostic assessment of malignant trophoblastic neoplasia could lead to promising survival rate with no uncurable complication and toxic effects.
authors.affiliation: Department of Gynecology, Liaoning Tumor Hospital, Shenyang 110042, China.
authors.forename: Yi-xun
authors.initials: YX
authors.lastname: Wang
authors.forename: Xin
authors.initials: X
authors.lastname: Zhang
authors.forename: Yu-lan
authors.initials: YL
authors.lastname: Guan
authors.forename: A-ying
authors.initials: AY
authors.lastname: Jang
authors.forename: Zai-qiu
authors.initials: ZQ
authors.lastname: Long
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002822:Choriocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D006063:Chorionic Gonadotropin / Q000097:blood; D003609:Dactinomycin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002820:Hydatidiform Mole, Invasive / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage; D009367:Neoplasm Staging / Q000379:methods / Q000592:standards; D011247:Pregnancy; D011379:Prognosis; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome; D014328:Trophoblastic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*
chemical_list: D006063:Chorionic Gonadotropin; D003609:Dactinomycin; D005472:Fluorouracil; D008727:Methotrexate